American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
- PMID: 29452019
- PMCID: PMC2795413
- DOI: 10.1200/JOP.0948502
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
Abstract
ASCO's update to its Clinical Practice Guideline on the use of pharmacologic interventions to reduce the risk of breast cancer addresses the roles of tamoxifen, raloxifene, aromatase inhibitors, and fenretinide in reducing risk for the disease.
Similar articles
-
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.J Clin Oncol. 2002 Aug 1;20(15):3328-43. doi: 10.1200/JCO.2002.06.029. J Clin Oncol. 2002. PMID: 12149307 Review.
-
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.Gynecol Oncol. 2009 Oct;115(1):132-134. doi: 10.1016/j.ygyno.2009.06.006. Gynecol Oncol. 2009. PMID: 19716939 Free PMC article. No abstract available.
-
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.J Clin Oncol. 1999 Jun;17(6):1939-55. doi: 10.1200/JCO.1999.17.6.1939. J Clin Oncol. 1999. PMID: 10561236 Review.
-
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.J Oncol Pract. 2010 Sep;6(5):243-6. doi: 10.1200/JOP.000082. Epub 2010 Aug 6. J Oncol Pract. 2010. PMID: 21197188 Free PMC article.
-
Update on breast cancer prevention.Oncology (Williston Park). 2003 Jun;17(6):799-805; discussion 808-10, 813. Oncology (Williston Park). 2003. PMID: 12846124 Review.
Cited by
-
Tuning surface properties of thiophene-based thin films on glass substrates for cancer cell adhesion, drug release control, and computational analysis.Sci Rep. 2025 Jun 20;15(1):20170. doi: 10.1038/s41598-025-05691-w. Sci Rep. 2025. PMID: 40542057 Free PMC article.
References
-
- Visvanathan K, Chlebowski RT, Hurley P, et al: American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235-3258, 2009 - PMC - PubMed
-
- National Cancer Institute: Breast Cancer Risk Assessment Tool. www.cancer.gov/bcrisktool
LinkOut - more resources
Full Text Sources
Other Literature Sources